D
지니너스
389030KOSDAQ39.5 / 100
Reference Date: 2026-10-23
Financial Score15.0 / 40
News Sentiment12.5 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 26.7% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Geninus focuses on genomics, bioinformatics, and the development of in-vitro diagnostic medical devices, leveraging advanced technologies such as NGS and PCR to provide innovative healthcare solutions in early cancer detection, liquid biopsy, and precision medicine. The company also conducts research on mutations and biomarkers to support disease prognosis prediction and personalized treatment strategies.
Number of Employees
59people
Average Salary
72.5M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
6.18Industry Average 1.200.0Point
5.2x industry avg (risky)
ROE
-110.87Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
18.72Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲27.5% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼8.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -59.7% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 1,429Won52-week high 6,27052-week low 1,429
1-month return0.0Point
1m -26.68% (strong drop)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0